Person looking at computer screen

U.S. Equity Series Fund

  • Vehicle Mutual Fund
  • Asset Class Equities

Overview

The GMO U.S. Equity Series Fund seeks to generate high total return by investing primarily in U.S. equities. The Fund’s benchmark is the Russell 3000 Index.

The Fund’s investment approach is grounded in the Global Equity team’s belief that, in the short term, equity markets exhibit exploitable inefficiencies as a result of irrational investor actions, the imperfect flow of information, and the participation of non-economic actors, while in the long term returns are ultimately driven by economic reality. The Fund aims to take advantage of this inefficiency by utilizing a multi-factor valuation model in conjunction with other methods, such as cross-asset signals and corporate alerts, to identify mispriced equity securities.

Facts

Doc Table
Benchmark Russell 3000

Share Class R6

CUSIP 380131300
Net Expense Ratio 1 0.51
Gross Expense Ratio 2 0.52

1 Net Expense Ratio reflects the reduction of expenses from fee reimbursements. The fee reimbursements will continue until at least June 30, 2020. Elimination of this reimbursement will result in higher fees and lower performance.

2 Gross Expense Ratio is equal to the Funds Total Annual Operating Expenses set forth in the Funds most recent prospectus dated June 30, 2019.

Performance

Quarter-End as of June 30, 2019(USD, %) | GMO U.S. Equity Series Fund R6

Table Caption
1-Year 3-Year 5-Year 10-Year ITD
U.S. Equity Series Fund 6.61 11.30 8.22 12.41 10.81
Russell 3000 8.98 14.03 10.19 14.67 10.98
  • U.S. Equity Series Fund 1
  • Russell 3000

Inception Date: September 18, 1985

Returns shown for periods greater than one year are on an annualized basis.

If certain expenses were not reimbursed, performance would be lower. Transaction costs, if any, are paid to the fund to offset the cost of portfolio transactions to invest or raise cash.

Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein.

1 The inception date above refers to the inception date of the GMO U.S. Equity Fund. Class R6 shares were first offered on January 1, 2012. The GMO U.S. Equity Series Fund is a feeder fund investing substantially all of its assets in shares of a corresponding master fund (i.e., a corresponding GMO Trust fund). Performance data quoted for GMO U.S. Equity Series Fund reflects the performance data of the corresponding GMO Trust master fund re-stated to reflect the fees and expenses associated with GMO U.S. Equity Series Fund.

Quarter-End as of June 30, 2019(USD, %) | GMO U.S. Equity Series Fund R6

Table Caption
QTD YTD 1-Year 3-Year 5-Year 10-Year ITD
U.S. Equity Series Fund 3.89 17.44 6.61 11.30 8.22 12.41 10.81
Russell 3000 4.10 18.71 8.98 14.03 10.19 14.67 10.98
  • U.S. Equity Series Fund 1
  • Russell 3000

Inception Date: September 18, 1985

Returns shown for periods greater than one year are on an annualized basis.

Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower.

Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein.

1 The inception date above refers to the inception date of the GMO U.S. Equity Fund. Class R6 shares were first offered on January 1, 2012. The GMO U.S. Equity Series Fund is a feeder fund investing substantially all of its assets in shares of a corresponding master fund (i.e., a corresponding GMO Trust fund). Performance data quoted for GMO U.S. Equity Series Fund reflects the performance data of the corresponding GMO Trust master fund re-stated to reflect the fees and expenses associated with GMO U.S. Equity Series Fund.

Month-End as of June 30, 2019(USD, %) | GMO U.S. Equity Series Fund R6

Table Caption
MTD QTD YTD 1-Year 3-Year 5-Year 10-Year ITD
U.S. Equity Series Fund 7.60 3.89 17.44 6.61 11.30 8.22 12.41 10.81
Russell 3000 7.02 4.10 18.71 8.98 14.03 10.19 14.67 10.98
  • U.S. Equity Series Fund 1
  • Russell 3000

Inception Date: September 18, 1985

Returns shown for periods greater than one year are on an annualized basis.

Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower.

Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein.

1 The inception date above refers to the inception date of the GMO U.S. Equity Fund. Class R6 shares were first offered on January 1, 2012. The GMO U.S. Equity Series Fund is a feeder fund investing substantially all of its assets in shares of a corresponding master fund (i.e., a corresponding GMO Trust fund). Performance data quoted for GMO U.S. Equity Series Fund reflects the performance data of the corresponding GMO Trust master fund re-stated to reflect the fees and expenses associated with GMO U.S. Equity Series Fund.

Year Ending December 31 (USD, %) | GMO U.S. Equity Series Fund R6

Calendar
U.S. Equity Series Fund Russell 3000
2018 -9.84 -5.24
2017 18.38 21.13
2016 13.51 12.74
2015 0.59 0.48
2014 9.25 12.56
2013 29.53 33.55
2012 12.74 16.42
2011 8.01 1.03
2010 8.75 16.93
2009 21.16 28.34
  • U.S. Equity Series Fund 1
  • Russell 3000

Inception Date: September 18, 1985

Returns shown for periods greater than one year are on an annualized basis.

Net of all fees and expenses after reimbursement by the Manager, but not transaction costs, if any. If certain expenses were not reimbursed, performance would be lower.

Performance data quoted represents past performance and is not indicative of future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance data may be lower or higher than the performance data provided herein.

1 The inception date above refers to the inception date of the GMO U.S. Equity Fund. Class R6 shares were first offered on January 1, 2012. The GMO U.S. Equity Series Fund is a feeder fund investing substantially all of its assets in shares of a corresponding master fund (i.e., a corresponding GMO Trust fund). Performance data quoted for GMO U.S. Equity Series Fund reflects the performance data of the corresponding GMO Trust master fund re-stated to reflect the fees and expenses associated with GMO U.S. Equity Series Fund.

Management

Harris_Simon

Simon Harris

Head of Global Equity (interim)

Mr. Harris is the interim head of GMO’s Global Equity team. In his decades at GMO, Simon has had extensive portfolio management, quantitative research, and team leadership experience including as the head of the UK Equity team prior to its merger with Global Equity. Previously, he also served as co-CEO of GMO UK Ltd. Prior to joining GMO in 1989, he earned his BSc in Mathematics from The City University (London). Mr. Harris is a Fellow of The Chartered Institute for Securities & Investment.

White_Josh

Josh White

Portfolio Manager

Dr. White is a quantitative analyst for GMO’s Global Equity team. Prior to joining GMO in 2015, he worked at Acadian Asset Management as a senior vice president working on quantitative research and portfolio management across much of their product line. Previously, he worked at the SEC where, in addition to other responsibilities, he was involved with disclosure and governance issues. Dr. White earned his A.B. in Economics from Harvard University and his Ph.D. in Business Economics from Harvard University.

Documents

Risks

Risks associated with investing in the Fund may include those as follows. (1) Market Risk - Equities: The market price of an equity may decline due to factors affecting the issuer or its industry or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares. (2) Management and Operational Risk: The risk that GMO's investment techniques will fail to produce desired results. (3) Focused Investment Risk: Investments focused in sectors, industries, or issuers that are subject to the same or similar risk factors and investments whose prices are closely correlated are subject to greater overall risk than investments that are more diversified or whose prices are not as closely correlated. For a more complete discussion of these risks and others, please consult the Fund's prospectus.

Disclosures

An investor should consider the fund’s investment objectives, risks, charges and expenses before investing. This and other important information can be found in the fund’s prospectus. Read the prospectus carefully before investing. Please see prospectus above. 

Each GMO Series Trust Fund is a feeder fund investing substantially all of its assets in shares of a corresponding GMO Trust Fund (i.e., a master fund). Under the master-feeder structure, each GMO Series Trust Fund's sole portfolio holding, other than cash, is shares of the corresponding GMO Trust Fund.

The GMO Trust funds are distributed in the United States by Funds Distributor LLC. GMO and Funds Distributor LLC are not affiliated.